AVROBIO, Inc. (NASDAQ:AVRO) Sees Significant Decrease in Short Interest

AVROBIO, Inc. (NASDAQ:AVRO) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 139,600 shares, a decline of 23.1% from the May 15th total of 181,600 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily volume of 225,500 shares, the days-to-cover ratio is currently 0.6 days.

AVROBIO Stock Performance

NASDAQ AVRO traded down $0.04 during trading on Friday, reaching $1.43. 127,665 shares of the company’s stock were exchanged, compared to its average volume of 225,706. The stock has a market cap of $64.19 million, a P/E ratio of 2.07 and a beta of 1.23. The company has a 50 day moving average price of $1.33 and a two-hundred day moving average price of $1.33. AVROBIO has a 1 year low of $0.88 and a 1 year high of $1.65.

AVROBIO (NASDAQ:AVRO) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. Research analysts forecast that AVROBIO will post -0.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Braden Michael Leonard bought 469,753 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $1.25 per share, with a total value of $587,191.25. Following the purchase, the insider now directly owns 4,471,380 shares of the company’s stock, valued at approximately $5,589,225. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 9.20% of the stock is currently owned by insiders.

Institutional Trading of AVROBIO

A number of institutional investors have recently bought and sold shares of AVRO. Gabelli Funds LLC purchased a new stake in shares of AVROBIO in the 4th quarter valued at about $467,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of AVROBIO in the 4th quarter valued at about $480,000. FNY Investment Advisers LLC lifted its holdings in shares of AVROBIO by 77.8% in the 4th quarter. FNY Investment Advisers LLC now owns 400,000 shares of the company’s stock valued at $544,000 after purchasing an additional 175,000 shares during the last quarter. Aldebaran Capital LLC purchased a new stake in shares of AVROBIO in the 3rd quarter valued at about $724,000. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of AVROBIO in the 3rd quarter valued at about $770,000. 62.63% of the stock is owned by hedge funds and other institutional investors.

About AVROBIO

AVROBIO, Inc, a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.